Healthcare investment firm Vivo Capital has led the $55-million funding round of Beijing Innocare, a biopharmaceutical company that develops treatment for cancer and autoimmune diseases, with CCB Capital also backing the round.
In a statement posted on its Chinese website, Beijing Innocare confirmed closing the $55-million funding round, which it said will be used to “promote innovation in drug research and development to serve the needs of Chinese patients”.
